Roche's gene therapy plans take Shape with $3B-plus biobucks deal Cerner taps Google, Geisinger vet Feinberg as new CEO. Here's how much he'll get paid in his new gig Pharma's reputation drops again. Could it foreshadow a return to the bottom? Vertex layers on bluebird bio pressure with $1.2B Arbor gene-editing pact Samsung plots $205B investment, massive hiring spree to ramp up CDMO, biosimilars and more KFF: Preventable COVID hospitalizations among unvaccinated cost U.S. health system $2.3B Novartis' Kymriah flops in earlier lymphoma use, where Gilead, Bristol Myers CAR-T rivals succeeded Rare disease data-focused AllStripes raises $50M to enhance medical record mining CMS delays enforcement of key parts of price transparency rule by 6 months Medtronic's earnings sidestep new COVID variants and faulty heart pumps, shielded by new products and tuck-in deals COVID-19 tracker: Samsung plots massive manufacturing expansion; Medtronic dodges delta's worst effects in latest earnings Nominations for Fierce Healthcare's 2021 Women of Influence Featured Story | By Amirah Al Idrus Roche may market the first FDA-approved in vivo gene therapy, but the company isn’t resting on its laurels. The Swiss pharma is teaming up with Shape Therapeutics on next-generation gene therapies for Alzheimer’s, Parkinson’s and rare diseases in a deal that could exceed $3 billion. read more |
| |
|---|
|
| | Webinar: Removing Antibody Drug Discovery's DNA Bottleneck Tuesday, September 14 | 2pm ET / 11am PT GPCRs have proven to be one of the most challenging targets for antibody drug development. In this webinar, we describe the use of next-generation DNA synthesis tools to overcome the DNA bottleneck in antibody-based GPCR drug discovery. Learn More. |
Top Stories By Heather Landi David Feinberg, who spent the past two years at Google leading the tech giant's health efforts, is moving over to lead Cerner after a three-month CEO search. The new CEO will make nearly $35 million through 2022, according to recent SEC filings. read more By Beth Snyder Bulik Pharma's reputation continues to slide, now down to 53% of consumers who still hold a positive view. The decline began after a February high of 62% approval, down to 60% in May and then 56% in June—and now down three more percentage points, according to The Harris Poll. read more By Kyle LaHucik Months after first-in-human gene-editing results made a splash around the world, Vertex is making a $1.2 billion edit to its CRISPR work through a new research pact with existing partner Arbor Biotechnologies. After dishing out $900 million upfront to CRISPR Therapeutics for sickle cell disease and beta thalassemia in April, Vertex is doubling down in its attempt to beat bluebird bio to market with a gene-editing therapy for those blood diseases. read more By Fraiser Kansteiner With a self-proclaimed “Super Plant” already on the way in South Korea, Samsung Biologics CEO John Rim said in January that the CDMO’s expansion was just getting started. He wasn’t kidding. The manufacturer’s parent company Samsung Group is investing an eye-popping 240 trillion won ($205 billion) across its biopharmaceutical, semiconductor and telecommunications businesses, among others. read more By Dave Muoio A new report from the Kaiser Family Foundation estimated 113,000 preventable COVID-19 hospitalizations in June and July alone. read more By Angus Liu Novartis’ Kymriah is losing its shot at a key market expansion opportunity in second-line lymphoma, where CAR-T rivals from Gilead Sciences and Bristol Myers Squibb recently found success. read more By Conor Hale With the goal of launching 100 new digital research programs across different rare diseases, AllStripes has secured $50 million to intensify its efforts at collating medical records and searching them for insights that could aid in drug development. read more By Robert King CMS has given insurers another six months to meet key requirements in a price transparency rule that goes into effect in January. read more By Andrea Park Thanks to a safety net stitched from a variety of new product launches and its continued focus on tuck-in acquisitions, Medtronic reported better-than-expected revenues of just under $8 billion for the first quarter of its 2022 fiscal year. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner Samsung Group is spending more than $200 billion in the coming years to bolster its manufacturing network. While Medtronic noticed a delta slowdown starting in late July in the U.S., the company was largely able to avoid its worst effects in its most recent earnings report. Plus more. read more By Heather Landi We are putting out the call for nominations to honor women across the healthcare industry—from physicians and CEOs to researchers and tech company execs—who are shaping the way healthcare of the future will be delivered. read more |
